Company / Profit Margin
CytomX Therapeutics, Inc. Profit Margin History
FY2016-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Profit Margin
-22.8%
FY2025
5-year range
-310.5% / 23.1%
FY2021-FY2025
Trend
-198.7%
vs FY2024
Sector context
#76 of 146
Health Care
What the data says
At -22.8%, CytomX Therapeutics, Inc.'s profit margin ranks #76 of 146 in the Health Care sector. Profit Margin has fluctuated over the past 10 years, ranging from -391.5% in FY2016 to 23.1% in FY2024.
Based on SEC 10-K filings.
-22.8% in FY2025 with a 5-year CAGR of +10.0%.
Declined from -0.6% to -22.8% over the past 2 years.
Health Care sector context is included.
Profit Margin over time
Growth rates
- 3-Year Change
- +164.0pp
- 5-Year Change
- +10.0pp
- 10-Year Change
- -
Sector benchmark
#76 of 146 in Health CareTop 52% of 146This company -22.8% Sector average -796.3%
▼
+97.1% above sector average
Key checks
Key Insights
- In FY2025, profit margin decreased 198.7% year-over-year.
- Currently 773.5pp above the Health Care sector average.
- Peak profit margin was recorded in FY2024.
- Lowest profit margin in the period was in FY2016.
Company context
Key Data Points
- Low Piotroski F-Score: 1/9 (multiple financial health concerns)
- Altman Z-Score -2.68 (distress zone, below 1.8 threshold)
- Strong profit margin: 23.1%
- Low earnings quality (accrual-heavy earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Profit MarginValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | -22.8% | -198.7% |
| FY2024 | 23.1% | +4221.4% |
| FY2023 | -0.6% | +99.7% |
| FY2022 | -186.8% | +39.8% |
| FY2021 | -310.5% | -847.6% |
| FY2020 | -32.8% | +81.6% |
| FY2019 | -177.8% | -25.1% |
| FY2018 | -142.2% | -136.3% |
| FY2017 | -60.2% | +84.6% |
| FY2016 | -391.5% | +77.0% |
As of FY2025 · SEC 10-K · Updated Jul 2, 2026